QTTB: Phase II data show robust efficacy for bempikibart in alopecia areata, supporting phase III plans
The session highlighted strong phase II results for bempikibart in alopecia areata, with robust efficacy and durable responses, and outlined a clear path to phase III with sufficient funding. The market opportunity is substantial, and biologics are expected to become the preferred treatment due to…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.